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Abstract
Background
Pregnancy induces drastic biological changes systemically, and has a beneficial effect on
some autoimmune conditions such as rheumatoid arthritis (RA). However, specific systemic
changes that occur as a result of pregnancy have not been thoroughly examined in healthy
women or women with RA. The goal of this study was to identify genes with expression pat-
terns associated with pregnancy, compared to pre-pregnancy as baseline and determine
whether those associations are modified by presence of RA.
Results
In our RNA sequencing (RNA-seq) dataset from 5 healthy women and 20 women with RA,
normalized expression levels of 4,710 genes were significantly associated with pregnancy
status (pre-pregnancy, first, second and third trimesters) over time, irrespective of presence
of RA (False Discovery Rate (FDR)-adjusted p value<0.05). These genes were enriched in
pathways spanning multiple systems, as would be expected during pregnancy. A subset of
these genes (n = 256) showed greater than two-fold change in expression during pregnancy
compared to baseline levels, with distinct temporal trends through pregnancy. Another 98
genes involved in various biological processes including immune regulation exhibited
expression patterns that were differentially associated with pregnancy in the presence or
absence of RA.
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Conclusions
Our findings support the hypothesis that the maternal immune system plays an active role
during pregnancy, and also provide insight into other systemic changes that occur in the
maternal transcriptome during pregnancy compared to the pre-pregnancy state. Only a small
proportion of genes modulated by pregnancy were influenced by presence of RA in our data.
Background
Pregnancy is known to have beneficial effects on rheumatoid arthritis (RA) in a number of ways.
New onset of RA is rare during the gestational period, suggesting that pregnancy may be protec-
tive against development of RA [1–3]. Pregnancy even appears to protect against RA onset
beyond the gestational period in the form of vaccine-like protection [4]. Further, women with
RA often experience a natural and dramatic improvement in disease activity during pregnancy
[5–8]. Some pregnancy-related factors that have been associated with the pregnancy-induced
improvement of RA disease activity include maternal-fetal HLA disparity [9] and microchimer-
ism [10]. The mechanism(s) behind the protective effects of pregnancy are, however, not entirely
clear. While there is no doubt that pregnancy induces drastic biological changes systemically, the
specific systemic changes that occur as a result of pregnancy and their effects on maternal health
have not been thoroughly examined. Hence, as a first step in examining the influence of preg-
nancy on RA, it is important that we gain a better understanding of systemic biological changes
associated with healthy pregnancy and that we determine whether pregnancy-induced biological
changes are altered by the presence of RA, irrespective of disease activity levels.
Global gene expression studies are well-suited to inform us on such changes that occur dur-
ing pregnancy. However, surprisingly little is known about pregnancy-induced systemic
changes in gene expression among healthy women because most gene expression studies in
pregnancy have focused on the maternal-fetal interface to understand how fetal tolerance is
established and maintained [11–13]. There have been very few gene expression studies on RA
pregnancy [14–17], all of which were focused on pregnancy-induced changes in disease activ-
ity. Thus, it still remains to be determined whether systemic biological changes associated with
pregnancy can be altered by the presence of RA, irrespective of disease activity levels.
In the present study, we have examined the hypothesis that the maternal immune system is
active during pregnancy among both healthy women and women with RA. We have examined
global gene expression profiles among 5 healthy women and 20 women with RA from pre-
pregnancy to the third trimester, to identify genes that exhibit pregnancy-induced changes in
expression. We also examined whether the presence of RA (irrespective of level of disease activ-
ity) influences pregnancy-associated gene expression.
Results
Study subjects
Overall, age at conception was similar among healthy women and women with RA: healthy
(mean±SD): 31.4 ± 5.8 years; RA: 31.6 ± 4.6 years (p = 0.99). The women with RA had the dis-
ease for a mean duration of 5.1 ± 3.3 years.
Medication use: Among the women with RA who had complete follow up (n = 13), 2 did not
take any medications while in the study, 7 took prednisolone and/or sulfasalazine before and/or
during pregnancy, and 4 took anti-TNF agents before pregnancy and in the first trimester. Of the
Pregnancy-Induced Systemic Gene Expression in Health and in Rheumatoid Arthritis
PLOS ONE | DOI:10.1371/journal.pone.0145204 December 18, 2015 2 / 15
Denmark (grant R87-A1477-B512). Author DJ
received the funding. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: ANOVA, analysis of variance; bp,
base pair; cDNA, complementary DNA; FDR, False
Discovery Rate; GEE, Generalized Estimating
Equations; GO, gene ontology; KEGG, Kyoto
Encyclopedia of Genes and Genomes; mRNA,
messenger RNA; RA, rheumatoid arthritis; RNA-seq,
RNA sequencing; rRNA, ribosomal RNA; TMM,
Trimmed Mean of M-values.
women on prednisolone and/or sulfasalazine, one took methotrexate before pregnancy, and one
was on hydroxychloroquine throughout pregnancy. The 7 women with incomplete follow up
took prednisolone or sulfasalazine (n = 6) or were not on medication (n = 1).
Data quality
The average number of paired-end reads across all samples was 73 million. Of these, an average
of 40% mapped to the reference transcriptome (S1 Fig). No significant differences were
observed in number of mapped reads across time points (ANOVA, p = 0.93). Sample replicates
processed in separate batches achieved a Pearson correlation of at least 0.97, following correc-
tion for batch effects (S2 Fig). After filtering out genes with low expression across all samples
and genes differentially expressed between replicate samples across batches, a total of 13,655
genes (39%) remained for downstream analyses.
Genes modulated by pregnancy in healthy women and women with RA
In the GEE models, of 13,655 genes analyzed, 4,710 had expression levels associated with preg-
nancy status over time (q<0.05), irrespective of whether a woman did or did not have RA. Path-
way analysis indicated that many of these genes were enriched pathways for: genetic information
processing, metabolism, signal transduction, cellular processes and organismal systems (immune,
endocrine, excretory, nervous), development, and disease pathways (Table 1). Among the genes
with pregnancy-associated expression, 256 genes showed greater than two-fold change in expres-
sion levels during pregnancy compared to pre-pregnancy levels among healthy women. These
had distinct temporal trends, with most being up-regulated as pregnancy progressed and others
showing reduced expression with advancing pregnancy stages (Fig 1). Significant changes in the
expression profiles compared to pre-pregnancy were observed during second trimester and were
maintained during third trimester. Examples of genes involved in immune system processes and
defense response that displayed a marked pregnancy-related up-regulation included: OLFM4,
MMP8, LTF, DEFA1, DEFA3, DEFA1B, CRISP3, CAMP, OLR1, LCN2, CD177, ABCA13 and
CEACAM8. Furthermore, genes involved in mast cell activation and immunoglobulin binding
were significantly downregulated in the second and third trimesters. Two such significant tran-
scripts were the Fc fragment of immunoglobulin Epsilon Receptor (FCER1A) andMembrane
Spanning 4-domains subfamily A member 2 (MS4A2).
Genes with pregnancy-associated expression modified by presence of
RA
In contrast to the genes with pregnancy-associated expression irrespective of the presence or
absence of RA, another 98 genes exhibited expression patterns during pregnancy that were
dependent on both pregnancy status and presence or absence of RA; these were identified
through the interaction term (RA×Pregnancy) in the GEE models. Functional classification
using the GO database revealed that these genes were involved in a variety of biological pro-
cesses including regulation of immune system (Table 2). Of these, thirteen genes displayed
greater than two-fold change in expression before and/or during pregnancy, compared to pre-
pregnancy levels among healthy women (Fig 2).
Genes with expression levels associated with presence of RA and/or
medication use
One hundred and eleven genes had expression levels that were associated with presence of RA
in the GEE models (q<0.05), irrespective of pregnancy status. The pathways and/or biological
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Table 1. Significantly enriched KEGG pathways among 4,710 genes associated with pregnancy.
KEGG pathways Genes identiﬁed q value*
(Genes in pathway)
Pathways enriched in genes up-regulated during pregnancy
Genetic information processing
Translation
Ribosome 51 (89) 7x10-24
Folding, sorting and degradation
Ubiquitin mediated proteolysis 30 (135) 2x10-3
Protein processing in endoplasmic reticulum 30 (165) 0.02
Proteasome 11 (44) 0.03
Replication and repair
Non-homologous end joining 5 (13) 0.04
Transcription
Spliceosome 24 (127) 0.03
Metabolism
Metabolism
Metabolic pathways 169 (1130) 5x10-4
Energy metabolism
Oxidative phosphorylation 31 (132) 6x10-4
Metabolism of other amino acids
Glutathione metabolism 13 (50) 0.02
Carbohydrate metabolism
Amino sugar and nucleotide sugar metabolism 14 (48) 4x10-3
Inositol phosphate metabolism 14 (57) 0.02
Galactose metabolism 8 (27) 0.03
Pentose phosphate pathway 8 (27) 0.03
Signal transduction
Signal transduction
MAPK signaling pathway 53 (268) 4x10-4
mTOR signaling pathway 14 (52) 8x10-3
Jak-STAT signaling pathway 30 (155) 0.01
Phosphatidylinositol signaling pathway 16 (78) 0.04
Cellular processes
Transport and catabolism
Phagosome 39 (152) 2x10-5
Lysosome 27 (121) 3x10-3
Endocytosis 46 (201) 4x10-5
Regulation of autophagy 9 (34) 0.04
Cell motility
Regulation of actin cytoskeleton 41 (212) 3x10-3
Cell growth and death
Apoptosis 20 (87) 8x10-3
Organismal processes
Immune system
Fc gamma R-mediated phagocytosis 29 (94) 1x10-5
Toll-like receptor signaling pathway 30 (102) 2x10-5
NOD-like receptor signaling pathway 17 (58) 1x10-3
B cell receptor signaling pathway 19 (75) 3x10-3
(Continued)
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Table 1. (Continued)
KEGG pathways Genes identiﬁed q value*
(Genes in pathway)
Leukocyte transendothelial migration 24 (116) 0.01
Fc epsilon RI signaling pathway 18 (79) 0.01
Hematopoietic cell lineage 19 (88) 0.02
T cell receptor signaling pathway 21 (108) 0.03
Chemokine signaling pathway 32 (183) 0.04
Natural killer cell mediated cytotoxicity 24 (136) 0.05
Development
Osteoclast differentiation 44 (128) 2x10-10
Endocrine system
Insulin signaling pathway 33 (138) 3x10-4
Adipocytokine signaling pathway 18 (68) 3x10-3
Excretory system
Collecting duct acid secretion 10 (27) 3x10-3
Nervous system
Neurotrophin signaling pathway 28 (127) 3x10-3
Long-term potentiation 15 (70) 0.03
Disease pathways
Infectious diseases: Bacterial
Epithelial cell signaling in Helicobacter pylori infection 19 (68) 1x10-3
Vibrio cholerae infection 13 (54) 0.02
Shigellosis 14 (61) 0.03
Bacterial invasion of epithelial cells 15 (70) 0.03
Infectious diseases: Parasitic
Leishmaniasis 21 (72) 4x10-4
Chagas disease 25 (104) 1x10-3
Toxoplasmosis 29 (132) 2x10-3
Cancers
Renal cell carcinoma 20 (70) 7x10-4
Pathways in cancer 55 (326) 7x10-3
Endometrial cancer 13 (52) 0.02
Acute myeloid leukemia 14 (57) 0.02
Non-small cell lung cancer 13 (54) 0.02
Glioma 15 (65) 0.02
Chronic myeloid leukemia 16 (73) 0.03
Pancreatic cancer 15 (70) 0.03
Pancreatic cancer 15 (70) 0.03
Thyroid cancer 8 (29) 0.04
Neurodegenerative diseases
Alzheimer's disease 40 (167) 5x10-5
Huntington's disease 41 (183) 2x10-4
Amyotrophic lateral sclerosis 15 (53) 4x10-3
Parkinson’s disease 27 (130) 7x10-3
Immune diseases
Rheumatoid arthritis 18 (91) 0.04
Endocrine and metabolic diseases
(Continued)
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processes that these genes are involved in are shown in Table 3. Our analyses also detected
genes with expression levels influenced by medication use; these were involved in immune
response, defense response, RNA binding, and transferase activity.
Discussion
Using samples from an ethnically homogeneous pregnancy cohort followed in real time from
pre-pregnancy, we have examined changes in global gene expression among healthy women
and women with RA using RNA-seq technology. Given that pregnancy-induced gene expres-
sion could not previously be examined relative to the pre-pregnancy state, our findings are
novel. We have identified genes that demonstrate altered expression during pregnancy com-
pared to the pre-pregnancy baseline, and shown how their temporal patterns of expression
change throughout pregnancy. These include several potentially novel genes that are at least
two-fold differentially expressed during pregnancy compared to before pregnancy. In addition,
we have also identified genes that demonstrate different temporal patterns of expression
through pregnancy between healthy women and women with RA; that is, their pregnancy-
associated expression patterns were altered by whether a woman was healthy or had RA.
Human pregnancy is known to induce extensive physiological changes in the mother,
involving almost every system. Our results at the gene expression level fit well in this context,
indicating systemic changes in maternal transcriptome spanning multiple cellular and organis-
mal systems, pathways and biological processes during pregnancy. Among the pathways that
we identified as being enriched in genes with pregnancy-associated expression, several were
related to immune function. This is especially relevant since pregnancy is known to be associ-
ated with immunological changes and challenges, not just locally at the maternal-fetal inter-
face, but also at the systemic level. The pathways identified relate to natural killer cell mediated
cytotoxicity, and signaling pathways involving Toll-like receptor, NOD-like receptor, T cell
receptor, and B cell receptor, suggesting that both innate and adaptive immune responses play
a role in pregnancy. Further, several of the genes that were the most highly up-regulated during
pregnancy are expressed in neutrophils, in line with previous reports of neutrophil activation
during pregnancy [18–20]. An overexpression of neutrophil-related genes, namely OLFM4,
MMP8, DEFA1 and CEACAM8, during pregnancy has also been reported by Heung et. al.
[21]. Our findings thus add support to mounting evidence that the maternal immune system is
active, and not generally immuno-suppressed during pregnancy [22].
Table 1. (Continued)
KEGG pathways Genes identiﬁed q value*
(Genes in pathway)
Type II diabetes mellitus 11 (48) 0.05
Pathways enriched in genes downregulated during pregnancy
Metabolism
Glycam biosynthesis and metabolism
N-Glycan biosynthesis 17 (49) 2x10-3
Disease pathways
Immune diseases
Primary imunodeﬁciency 19 (35) 2x10-7
* q value refers to the FDR-adjusted p value associated with the KEGG pathways enriched in pregnancy-associated genes. Pathways are grouped into
broad functional categories.
doi:10.1371/journal.pone.0145204.t001
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Previous studies of systemic gene expression changes that occur in the mother during
healthy pregnancy have been few and the findings inconsistent. Some studies reported no sig-
nificant differences between pregnancy and post-partum expression profiles of healthy women
Fig 1. Heatmap showing temporal trends in expression among genes with pregnancy-associated expression, compared to pre-pregnancy levels
in healthy women. Log-transformed (log2) values of the average fold change in expression compared to pre-pregnancy levels are plotted. Only genes that
exhibited 2-fold or higher change in expression (compared to healthy pre-pregnancy baseline levels) in any trimester are shown. These patterns were similar
in healthy women and in women with RA.
doi:10.1371/journal.pone.0145204.g001
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[14, 17]. Other reports share some degree of overlap in genes/pathways that we have identified
as being modulated by pregnancy. For example, a study of peripheral blood mononuclear cells
(PBMC) profiles using microarray data identified genes differentially expressed during and
after pregnancy [16]. Pathways that overlapped with our findings included those for: apoptosis,
cancer, Fc gamma R-mediated phagocytosis, natural killer cell-mediated cytotoxity, and signal-
ing pathways involving MAPK, T cell receptor, Toll-like receptor, and adipocytokine. In a lon-
gitudinal study of 11 women followed from the first trimester through 6 weeks post-partum,
pairwise analyses of microarray and RNA-seq data from cell-free plasma RNA identified 16
genes in common with our findings [23]. Of interest, several genes such as MMP8, S100P,
LIN7A, ZNF438, TCN1, B3GNT5, PLEK2 and PAPPA showed similar temporal changes in
expression as pregnancy progressed as observed in our study. A small (n = 4) study of cell-free
plasma comparing RNA-seq data from before and after delivery identified several genes with
pregnancy-associated expression that were also found in our data [24].
The inconsistencies in findings between these previous studies and our study may be
accounted for by a number of factors. First, whilst these studies used either cell-free sera or
PBMC as the source of total RNA, our source of total RNA included both the cellular and cell-
free fractions of whole blood. Second, these few studies have identified pregnancy-related
changes using postpartum data as baseline. However, the postpartum state is itself associated
with major changes such as lactation, increased risk of some cancers [25], depression [26, 27],
and significant immunologic changes as reflected by increased risk of some autoimmune dis-
eases [1, 28, 29]. Therefore, the appropriate baseline when identifying pregnancy-specific
changes is the pre-pregnancy state, which was not available in these studies. Third, we used
GEE models to make the most of the data available at all time points. Pairwise analyses of data
available from the same subjects across time points [23, 24] limit the power of the analyses.
Table 2. Functional categories of genes with expression patterns differentially associated with preg-
nancy in presence or absence of RA.
Biological process / Molecular
function
Genes
Regulation of immune system
process
HLA-DRB3, IL15
Metabolic process ACAD11, DECR2, LCAT, PKD2, PNPLA2, IL15, CAMKK1
Regulation of catalytic activity PKD2, IFI27, CAMKK1
Hormone transport HLA-DRB3, CACNA1C
Cellular response to osmotic
stress
PKD2, RCSD1
Neurogenesis MAP1S, CTHRC1, CACNA1C, USH2A, ARHGDIA
Tissue morphogenesis PKD2, CTHRC1, CCM2
Voltage-gated calcium channel
activity
PKD2, CACNA1C
Endothelial cell migration EPHB4, HDAC5
Protein binding TNNI2, CACNA1C, RPH3AL, USH2A, DAAM2, RCSD1, MAP1S,
PKD2, FAM101B, MYO7B, SH2D4A, SYTL2
Cofactor binding SQLE, ACAD11, HSD11B2, MTO1
Hydrolase activity CES2, HDAC5, LCAT, PNPLA2
Genes up-regulated in healthy pregnancy are shown in normal font, genes downregulated in healthy
pregnancy are shown in italics, genes up-regulated in RA pregnancy are not underlined and genes
downregulated in RA pregnancy are underlined.
doi:10.1371/journal.pone.0145204.t002
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Additionally, in cases where data on each woman was available at only one time-point (i.e.
cross-sectional data) [16], changes identified between time points may have been in part due to
between-subject variability. Fourth, while several of the previous studies were based on micro-
array data [17, 23], we used the more accurate and reliable RNA-seq technology [30, 31].
Fig 2. Heatmap showing genes with pregnancy-associated expression patterns that are altered by
presence of RA. Log-transformed (log2) values of the average fold change in expression compared to
baseline (i.e. pre-pregnancy levels among healthy women) are plotted for healthy women and for women with
RA. Only genes that exhibited 2-fold or higher change in expression (compared to healthy pre-pregnancy
baseline levels) in any trimester are shown.
doi:10.1371/journal.pone.0145204.g002
Table 3. KEGG pathway and Gene Ontology Biological process categories of the genes showing association with RA.
Pathway / biological process Genes
mTOR signaling pathway ULK1, AKT1
Toll-like receptor signaling pathway IKBKG, AKT1, TOLLIP
Metabolic pathways MAN2A2, GAA, GALC, CSGALNACT1, MAOA, NDUFV3, ABAT, LIPC, DBT, PISD
Fatty acid metabolic process FADS1, FADS2, FADS3, ABAT, AKT1, LIPC, SCAP
Cellular polysaccharide metabolic
process
GAA, AKT1, PYGM, CSGALNACT1
Intracellular transport of viral
material
VPS37C, VPS37B
Neurotransmitter catabolic process MAOA, ABAT
t-RNA binding SLFN11, IGHMBP2
DNA helicase activity IGHMBP2, HELB
Catalytic activity GAA, TUBB2A, PYGM, SPTSSB, ACAP1, ULK1, ERCC4, RNF43, IGHMBP2, ABAT, GRK6,
KIF21B, PISD, SPPL2A, FADS3, ECHDC3, TPST1, NDUFV3, DBT, UBE2M, CARS2,
DCTN1, PLK3, FADS1, FADS2, AKT1, ADCK3, GALC, HELB, UFSP1, PPM1F, USP10,
PGLYRP1, LIPC, ALK, MAN2A2, PRDX5, MAOA, CSGALNACT1, DTD1, TRIM36
GTPase activator activity ARHGAP9, GMIP, ARHGAP27, ACAP1, RAP1GAP2
Up-regulated genes are shown in normal font and downregulated genes are in italics.
doi:10.1371/journal.pone.0145204.t003
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Our findings relating to genes that have pregnancy-related patterns altered by presence of
RA are novel. Several of the genes identified have previously been implicated in RA. For exam-
ple, HLA-DRB3 and G0/G1 Switch 2 (G0S2) expression have been reported to predict response
to anti-TNF therapy [32, 33], while Interferon, Alpha-Inducible Protein 27 (IFI27) and Tropo-
nin I type 2 (TNNI2) appear to be involved in RA onset or progression [34, 35]. To our knowl-
edge, it had thus far not been demonstrated that these genes can be modulated by both RA and
pregnancy status. It is not clear yet whether and how the remaining genes that exhibited preg-
nancy-related patterns altered by presence of RA, may be involved in the disease.
Our study does have strengths as well as limitations. The sample size was small, but longitu-
dinal samples available from the majority of subjects enabled us to use GEE models to enhance
power and to eliminate noise due to between-subject variability and time-stable confounders.
The ethnic homogeneity of our study population also was an advantage. We cannot eliminate
the possibility of technical bias and/or batch effects having been introduced in the data. How-
ever, we randomized sample order prior to any sample processing, used a block design for
sequencing, and at the data processing step, we used sample replicates to assess and mitigate
batch effects. We also adjusted for any residual batch effects in the statistical models. Although
we adjusted for medication use in the model, we did not adjust for specific medications that
may have an effect on the immune system and/or dosage due to the heterogeneity in medica-
tion use. Because our goal was to identify overall systemic gene expression changes resulting
either from altered expression of specific genes or from changes in cell proportions, we also did
not examine whether proportions of different cell types in blood samples changed across time
points. We nevertheless adjusted for medication use in the analysis, which should have cor-
rected for drug-induced changes in cell type proportions. The use of total RNA from whole
blood may also mean that expression profiles of neutrophils may have dominated a large part
of the observed expression patterns. Some genes expressed by neutrophils such as MMP8, LTF,
CRISP3, CD177 and DEFA4 did exhibit significant changes in expression during the course of
pregnancy since neutrophils appear to have an active role in later stages of pregnancy and in
labor [36]. However, the sensitivity of RNA-seq technology enabled us to also detect transcripts
that were not neutrophil-specific, including those specific to cell types present in low propor-
tions in blood. We have not attempted to separate RA-associated gene expression from disease
activity-associated gene expression because the women with RA showed a broad range of dis-
ease activity, ranging from remission to high disease activity, both before and during preg-
nancy. Since the pregnancy-related gene expression changes were obtained by averaging over
all RA patients, we do not expect them to have been induced by specific disease activity, but by
presence of the disease in general.
Conclusions
In summary, our findings support the hypothesis that the maternal immune system is active
during pregnancy, as depicted by the significant changes in expression of immune response
genes in the global transcriptome of both healthy women and women with RA. We have identi-
fied several genes that demonstrate pregnancy-associated expression patterns that were similar
in healthy women and in women with RA, with only few genes showing altered expression in
the presence of RA. These findings broaden our understanding of pregnancy-associated sys-
temic changes in the maternal transcriptome among healthy women and women with RA.
While it is not yet known how these changes in gene expression might influence the decreased
risk of RA onset during pregnancy or contribute to pregnancy-induced amelioration of RA,
these results, though still exploratory, may represent a first step towards elucidating the benefi-
cial influence of pregnancy on RA.
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Methods
Study subjects
Twenty five women of Danish descent, 5 healthy and 20 with RA, were recruited and enrolled
in a pregnancy cohort in Denmark. All 5 healthy women and 14 of the women with RA were
enrolled before pregnancy; another 6 women with RA were enrolled after they conceived, in
the first (n = 2), second (n = 1) and third (n = 3) trimesters. One of the 14 women with RA
enrolled before pregnancy was not followed after she conceived because she had a miscarriage.
Study subjects were followed prospectively from the time of enrollment through the third tri-
mester. Subjects with RA fulfilled the 1987 revised American College of Rheumatology criteria
for RA [37]. The study was approved by the Ethics Committee for Region Hovedstaden (Den-
mark), the Danish Data Protection Agency, and the Children’s Hospital Oakland Research
Institute Institutional Review Board. All subjects provided written informed consent prior to
enrolment.
Sample collection and processing
Blood samples were drawn into PAXgene RNA tubes at 4 time points: before conception and
once every trimester during pregnancy (gestational weeks 6–8, 24 and 32). Data on medication
use during the 3 months prior to the blood draw were also collected at the same time points
from the subjects with RA. Total RNA was extracted from frozen blood samples using the
PAXgene Blood RNA Isolation kit according to the manufacturer’s protocol. RNA integrity
was assayed using 2100 Bioanalyzer and D1000 ScreenTape (Agilent Technologies). The Illu-
mina TruSeq RNA sample preparation kit was used to generate barcoded cDNA libraries
depleted of ribosomal RNAs (rRNAs) and globin mRNAs. Pooled libraries were sequenced on
an Illumina HiSeq2500 instrument to generate on average 60 million paired-end reads of 100
bp length. cDNA library preparation and sequencing were performed in two batches. Sample
replicates were included in both batches to assess and correct for batch effects. To minimize
confounding from experimental effects introduced by variations in library preparation, flow
cells or lanes, sample order was randomized prior to library preparation and a blocking design
[38] was adopted for sequencing.
Bioinformatic analyses
The raw sequence reads (FASTQ format) were aligned to cDNA sequences of the human
GRCh38 reference assembly available in Ensembl using the Bowtie2 (v2.2.5) algorithm [39].
The reads were mapped as concordant paired reads with stringent read and reference gap pen-
alties (—rdg 6,5—rfg 6,5—score-min L,-.6,-.4) to report all alignments. The resulting align-
ments in SAM format were converted to BAM format using SAMtools [40]. Transcript
abundances were calculated from the BAM files using eXpress (v1.5.1) with default settings
[41]. BioMart [42] annotations were used to map the transcript Ensembl identifiers to their
associated gene loci using in-house python scripts. Gene-level quantifications were determined
by combining the transcript-level quantifications onto their associated gene loci. To remove
unwanted variation in the transcriptome profiles associated with batch effects, genes which
showed at least 10-fold difference in expression (FDR-adjusted p-value< 0.05) across two
batches in replicate samples were filtered out, and correlations in expression levels between
batches were computed. Genes with very low read counts across all samples were also removed.
To adjust for variable sequencing depths between samples, the raw gene counts were normal-
ized using a weighted trimmed mean of the log expression ratios (Trimmed Mean of M values
[TMM] algorithm) as implemented in the edgeR Bioconductor package [43, 44].
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Statistical analyses
Longitudinal regression models. To examine associations between repeated measures of
gene expression levels over 4 time points corresponding to different pregnancy status (pre-preg-
nancy, first, second and third trimesters), Generalized Estimating Equations (GEE) models were
fitted, with robust estimation, using normalized gene counts as the outcome variable and preg-
nancy status as the main explanatory temporal variable. Covariates included in the models were
presence of RA (present/absent), medication use before/during pregnancy (yes/no), and sequenc-
ing batch (1/2). To determine whether associations between gene expression levels and preg-
nancy status were modified by the presence of RA, an interaction term (RA×Pregnancy) was also
included in the model. These models allowed within-person correlations in the repeated mea-
sures of the data to be adjusted for. A negative binomial link function was used to handle the
over-dispersion in RNA-seq gene counts. Both independent and exchangeable correlation struc-
tures were tested. Correction for multiple testing was achieved using the Benjamini-Hochberg
False Discovery Rate (FDR) method [45]. We refer to the FDR-adjusted p values as q values [46]
henceforth. A threshold of q<0.05 was used to assess statistical significance of associations tested.
All statistical computations were performed using STATA version 13.1 software.
Temporal patterns in expression levels. For genes demonstrating statistical association
with pregnancy status, temporal variations, i.e. from pre-pregnancy to the third trimester, in
gene expression levels (log-transformed normalized gene counts) among healthy women and
women with RA were examined using pre-pregnancy expression levels in healthy women as
reference. The ratio of average expression levels at each time point relative to the average
expression levels in the reference group was evaluated as the mean fold change, and these were
plotted as a heat map.
Gene ontology and pathway analyses. Sets of genes demonstrating evidence of associa-
tion with pregnancy status were analyzed for over-representation of biological processes and
pathways terms in the Gene Ontology (GO) and KEGG databases using a hypergeometric test
implemented in WebGestalt [47]. A q value<0.05 was used to define significant enrichment.
Supporting Information
S1 Fig. Mapped Read Counts. Bar plot showing total number of mapped reads for each sam-
ple from healthy women and women with RA.
(TIF)
S2 Fig. Scatter plots showing high correlation between replicates of the same biological
sample. The plots and correlations shown are representative of 3 independent sets of sample
replicates included in the 2 batches of samples, to correct for batch effects. In the left panel,
log-transformed gene-level counts from technical replicates of the same biological sample
(sample 1) are plotted against each other. These technical replicates represent independent
cDNA libraries prepared within a single batch of samples (batch 1). The Pearson correlation
between the within-batch replicates was 0.99. In the right panel, the log-transformed gene-level
counts are plotted for sample 1/batch 1 on the x-axis and for a technical replicate of sample 1
prepared as part of a separate batch of samples (replicate 2/batch 2) on the y-axis, after correc-
tion for batch effects. The Pearson correlation for these between-batch replicates was 0.98. (
To accommodate genes which had a read count of zero, log(counts+1) was used.)
(TIF)
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